The MOA of Senicapoc: A Gardos Channel Blocker

Lara Sullivan, MD, President and Founder at SpringWorks Therapeutics discusses the mechanism of action of Senicapoc (a Gardos channel blocker), an emerging treatment for Hereditary Xerocytosis, a genetic disorder in which red blood cells become dehydrated due to loss...

Still’s Disease Overview

Len Walt, Vice President, Head of Medical Affairs, Sobi in North America, provides an overview of Still’s disease, a rare inflammatory disorder that affects the entire body (systemic disease). Still’s disease, a disorder featuring inflammation, is...

Resources Available for Patients Suffering from Polycythemia Vera

David Gelly is a patient with Polycythemia Vera (PV). In this interview he discusses some of the resources available to patients with this rare condition, including Voices of MPN. PVs are a group of rare blood cancers called Myeloproliferative Neoplasms (MPNs). MPNs...

Potential Market for Actinium’s Iomab-B

Sandesh Seth, Executive Chairman of Actinium Pharmaceuticals discusses the potential market for Iomab-B. Iomab-B via the monoclonal antibody BC8, targets CD45, an antigen widely expressed on leukemia and lymphoma cancer cells, B cells and stem cells. BC8 is linked to...
  • Sign up
Lost your password? Please enter your username or email address. You will receive a link to create a new password via email.
We do not share your personal details with anyone.